Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

Abstract

Over one-third adalimumab-treated patients are dose escalated within a median of 5 months. Higher BMI and secondary non-response to IFX treatment are predictive for a dose escalation during adalimumab treatment.